Molecular immunotherapy for oral cancer based on the host immunity diagnosis.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25293412
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: Ehime University
• Principal Investigator: Hamakawa Hiroyuki 愛媛大学, 医学(系)研究科(研究院), 教授 (20127905)
• Co-Investigator(Kenkyū-buntansha): Nakashiro Koh-ichi 愛媛大学, 大学院医学系研究科, 准教授 (90314880) ; Goda Hiroyuki 愛媛大学, 医学部付属病院, 講師 (00464371)
• Co-Investigator(Renkei-kenkyūsha): Okamoto Masato 北里大学, 薬学部, 特任教授 (10243718)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 口腔癌 / 免疫療法 / バイオマーカー

Outline of Final Research Achievements

Recently immunotherapy are promising cancer therapy. However, the biomarker evaluating immunological condition is not established. In the present study, We have identified IL-6 and 8 as a critical biomarker in oral cancer. We showed that the serum IL-6 level tended to negatively correlate with favorable outcome. And IL-6 has important roles in cancer progression via angiogenesis. IL-8 may be involved in poor clinical outcomes via generation of CD163-positive M2 macrophages. These findings obtained from this study lead to development of personalized immunochemotherapy for oral cancer patients.

Free Research Field

外科系歯学